Purpose To estimate the prevalence of lens opacities in a group of elderly people and evaluate their relation with diverse risk factors. Methods Cross-sectional observational study of the cohort of all persons over the age of 64 years from an urban area and a rural nucleus of the province of Cuenca, Spain. Information on sociodemographic parameters and smoking was compiled using a structured questionnaire. A physical examination was made in which weight, height, and waist circumference were measured, and an ophthalmologic examination was made of visual acuity and lens opacities. Cataracts were classified using the method of the WHO cataract group. Results The study included 1155 subjects out of 1435 elderly persons who were invited to participate (response rate 80.5%). The prevalence of cataract in men was 69.2% and in women, 65.5% (p>0.05). The percentage of persons with aphakia/pseudophakia was 17.8% in men and 17.5% in women (p>0.05). In a logistic regression model, age, obesity of more than 35 kg/m2, and low educational level were associated with the presence of cataract or aphakia/pseudophakia. Conclusions The prevalence of cataract in people over 64 years is similar to that of other countries, but the prevalence of subjects with previous surgery for cataracts is the highest reported in the literature. Age, body mass index of more than 35 kg/m2, and low educational level were associated with the probability of having cataracts or undergoing surgery for cataracts. (Eur J Ophthalmol 2007; 17: 29–37)

No abstract

A novel and suitable energy‐dispersive X‐ray fluorescent (EDXRF) device, currently at the prototype stage, the Project OXIRIS (Orthovoltage X‐Ray–Induced Radiation System), is presented for the simultaneous detection and treatment of cancer diseases. Monte Carlo simulation and experimental results of EDXRF signals from a small deep artificial tumor consisting of a solution of gold nanoparticles bio‐targeted and immersed in a tissue‐bioequivalent matrix are presented and compared. Briefly, the device consists of a dynamic orthovoltage X‐ray fluence concentration coupled to confocal with an EDXRF system along with a sample holder for 3D scanning; all integrated and controlled by a dedicated software capable of controlling the whole operation functionalities: the X‐ray source, the rotating arm, the sample holder, and the detection system. The software also includes dedicated subroutines for X‐ray fluorescent spectra processing to correlate K‐lines signal at each acquisition position with the corresponding high atomic number elements' concentration to produce a 3D distribution according to the user‐defined grid. The confocal configuration ensures that the detected signal comes exclusively from the excited volume as defined by the bulk of the focal spot. Hence, the 3D image is achieved by scanning the sample holder through the movement of the sample‐carrier stretcher moved by step motors in the 3 coordinated axes. The feasibility of the proposed methodology and the design of the prototype have been successfully demonstrated experimentally, targeting gold nanoparticles in water‐equivalent phantoms.

758 Background: Accurate disease monitoring in PBC is instrumental for optimal therapeutic decision-making. CA 19-9 is the most utilized biomarker, though it has limited sensitivity/specificity and cannot be used in CA 19-9 non-secretors (n-S). ctDNA is a potentially helpful monitoring aid and surrogate for PBC n-S. Serial ctDNA could identify emerging resistant driver mutations. Our study prospectively examined ctDNA in PBC patients receiving treatment and retrospectively correlated it with clinical response. Methods: We performed genomic testing of ctDNA from metastatic PBC patients’ plasma from 11/2016 to 08/2019. This included 77 patients, of those, 18 had >1 ctDNA measurement with 49 correlative data points in total. Demographics, serial CA 19-9 levels and imaging results were collected. ctDNA analysis by parallel sequencing of amplified target genes (74) using Guardant360 was obtained. We correlated imaging and CA 19-9 responses with molecular alterations in patients receiving systemic chemotherapy. Descriptive statistics and logistic regression of the data was performed. Results: Of those included, median age was 66 yo, 50% male, and 92% pancreatic ductal adenocarcinoma. Baseline ctDNA showed 103 mutations including TP53 12.6%, KRAS 9.7%, MET 6.8%, APC, ARID1A and NF1 4.8% each, and others < 3%. 44% of patients were n-S with 75% having both TP53 and KRAS mutations. APC, ARID1A, and NF1 were only present in n-S. 91% vs 90% KRAS and 84% vs 78% TP53 of n-S and secretors (S), respectively, had correlation between ctDNA levels and imaging response. S TP53 and KRAS mutations correlated to CA19-9 levels and scans in 78% and 70% responses. New TP53 subclonal variant mutations were the most common resistance mutations for all progressions (75%). A logistic regression model of imaging progression on change in CA19-9 secretion and TP53 or KRAS expression was not statistically significant. Conclusions: Baseline ctDNA level changes ( TP53 and KRAS) can potentially act as a biomarker of response in PBC, specifically in n-S. TP53 subclonal mutations were the most common resistant alterations at progression and can be explored as future targets. This is being explored in larger prospective trials.

No abstract